Objective: Occult central nervous system (CNS) symptoms not recognized by people living with HIV (PLWH) receiving efavirenz or their clinicians could occur and impact people’s quality of life. The aim of this study was to determine whether CNS parameters improve in PLWH when switching from efavirenz to rilpivirine. Methods: PLWH receiving tenofovir disoproxil fumarate, emtricitabine, efavirenz (Atripla™) with undetectable HIV RNA, and no CNS symptoms were switched cART to tenofovir disoproxil fumarate, emtricitabine, rilpivirine (Eviplera™). CNS parameters including sleep, anxiety, and depressive symptoms were evaluated using patient-reported outcome measures at baseline, 4, 12, and 24 weeks after switching therapy. A median CNS score was d...
The NNRTI efavirenz has long been one of the most frequently employed antiretroviral drugs in the mu...
Background: It is acknowledged that almost half of patients initiated on efavirenz will experience a...
Although switching antiretroviral therapy (ART) in people with human immunodeficiency virus experien...
Objective: Occult central nervous system (CNS) symptoms not recognized by people living with HIV (PL...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not Etravirine (ETR...
BACKGROUND: Efavirenz (EFV) association with neurocognitive impairment is debated. Whether switching...
Neuropsychiatric symptoms in human immunodeficiency virus (HIV)-infected patients may be a late comp...
Background: Different antiretroviral therapies (ARTs) may have differing effects on central nervous ...
We assessed changes in functional connectivity by fMRI (functional magnetic resonance imaging) and c...
Background:Efavirenz is well known for its clinical cognitive side effects. Even asymptomatic patien...
BACKGROUND: Efavirenz is well known for its clinical cognitive side-effects. Even asymptomatic patie...
Background: Efavirenz is part of the first-line treatment for HIV patients including South Africa wi...
Introduction: Efavirenz is a potent, safe and tolerable non-nucleoside reverse transcriptase inhibit...
Rilpivirine is safe and effective in HIV-naïve patients with low baseline HIV-RNA or in switch strat...
Neurocognitive (NC) complications continue to afflict a substantial proportion of HIV-infected peopl...
The NNRTI efavirenz has long been one of the most frequently employed antiretroviral drugs in the mu...
Background: It is acknowledged that almost half of patients initiated on efavirenz will experience a...
Although switching antiretroviral therapy (ART) in people with human immunodeficiency virus experien...
Objective: Occult central nervous system (CNS) symptoms not recognized by people living with HIV (PL...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not Etravirine (ETR...
BACKGROUND: Efavirenz (EFV) association with neurocognitive impairment is debated. Whether switching...
Neuropsychiatric symptoms in human immunodeficiency virus (HIV)-infected patients may be a late comp...
Background: Different antiretroviral therapies (ARTs) may have differing effects on central nervous ...
We assessed changes in functional connectivity by fMRI (functional magnetic resonance imaging) and c...
Background:Efavirenz is well known for its clinical cognitive side effects. Even asymptomatic patien...
BACKGROUND: Efavirenz is well known for its clinical cognitive side-effects. Even asymptomatic patie...
Background: Efavirenz is part of the first-line treatment for HIV patients including South Africa wi...
Introduction: Efavirenz is a potent, safe and tolerable non-nucleoside reverse transcriptase inhibit...
Rilpivirine is safe and effective in HIV-naïve patients with low baseline HIV-RNA or in switch strat...
Neurocognitive (NC) complications continue to afflict a substantial proportion of HIV-infected peopl...
The NNRTI efavirenz has long been one of the most frequently employed antiretroviral drugs in the mu...
Background: It is acknowledged that almost half of patients initiated on efavirenz will experience a...
Although switching antiretroviral therapy (ART) in people with human immunodeficiency virus experien...